Scientists Found the Glitch in mRNA Vaccines, and How to Fix It

Your cells read mRNA the way you read a recipe — three letters at a time. Scientists Found the Glitch in mRNA Vaccines, and How to Fix It: a new study has traced why one key ingredient in mRNA vaccines can occasionally make that reading go wrong, and handed vaccine developers a set of design rules to stop it. The study, published in Nature Communications in October 2026, comes from a team at the Max Planck Institute for Multidisciplinary Sciences in Göttingen, Germany, led by Panagiotis Poulis and Marina Rodnina.

To understand the glitch, picture a ribosome sliding along an mRNA strand, reading three-letter codons and snapping the matching amino acids into a growing protein. Modern mRNA vaccines swap out a natural building block, uridine, for a modified version called N1-methylpseudouridine. That swap is deliberate: it quiets unwanted immune alarm bells and helps cells produce more of the target protein. But there is a trade-off. At certain sequences the ribosome can slip forward by a single letter, a glitch called frameshifting, and from that point on every codon is misread, producing an unintended protein.

The researchers combined experiments in human cells with a fully reconstituted translation system, then watched individual ribosomes in real time with single-molecule fluorescence microscopy. According to the study, the modified building block loosens the transfer RNA’s grip on the mRNA, making a one-letter slip more likely at so-called slippery sequences. The Pfizer-BioNTech COVID shot BNT162b2 contains six such slippery motifs, while Moderna’s mRNA-1273 contains three. In lab tests, the slip rate on modified sequences ran from about one percent to just under three percent — low, but measurable.

This is not the first time scientists have noticed the slip. In December 2023, a Cambridge team reported in the journal Nature that the same modification could trigger frameshifting, and found immune cells in vaccinated people that recognized the misbuilt proteins. The new work goes further: it pinpoints the exact molecular trigger and shows how to design around it, turning an observation into an engineering rule.

The fix is in the code

Here is the elegant part. Frameshifting only happens at particular sequences, and those sequences can simply be rewritten. The team showed that changing a slippery UUU C sequence to UUC C — which encodes the exact same amino acid — almost completely abolished the errors. “Our study provides a rule set for designing mRNA vaccines and therapeutics,” Poulis says. By steering clear of slippery sequences, developers can keep the benefits of modified mRNA while cutting the misbuilt proteins. Rodnina puts the design challenge simply: future mRNAs must be judged on two things at once, how well they calm unwanted immune activation and how faithfully they are translated.

That is why it matters that Scientists Found the Glitch in mRNA Vaccines, and How to Fix It now, before the platform expands further. The principle reaches well beyond COVID shots. The researchers say the same rules apply to any mRNA-based product, from shots against other infectious diseases to personalized cancer vaccines, which tailor mRNA to a patient’s own tumor mutations. Reporting on the findings, the team notes the approach could reduce unintended translation products across the whole mRNA therapeutics platform.

Why your next flu shot cares

The mRNA platform is moving fast into vaccines you are far more likely to take. Moderna’s mRNA flu shot, mFLUSIVA, won US approval in August 2026 for adults over 50 after a phase-three trial of more than 40,000 people found roughly 27 percent lower relative risk of flu illness than the standard shot, as reported by News Medical. Europe licensed the first combined COVID-and-flu mRNA shot, mCOMBRIAX, in April 2026. An mRNA RSV vaccine is already on pharmacy shelves, and personalized mRNA cancer vaccines are moving through clinical trials.

None of this is a safety alarm about the shots already in arms. The slip is rare, and vaccine researchers stress that the value of the new work is preventive: bake the rules into the design of future mRNAs so the errors barely happen at all. The German team describes its findings as a design guide for the next generation of vaccines and therapeutics, not a verdict on the current ones.

That is the bigger picture for anyone who will roll up a sleeve in the coming years. The mRNA platform went from pandemic emergency tech to a toolkit for flu, RSV, and cancer in under a decade, and each new product inherits the lessons of the last. This time the lesson is written into the code itself: pick the right letters, and the ribosome reads the recipe exactly as intended. Scientists Found the Glitch in mRNA Vaccines, and How to Fix It — and the fix is already written into the playbook for the next generation of shots.